### FLAIL MITRAL VALVE

ECHOCARDIOGRAPHY IN THE INTENSIVE CARE UNIT

February 9, 2019.

Hakam Alzaeem, MD Consultant Cardiologist Non-invasive Lab - HMC

# Overview

- > Introduction and Anatomy.
- > Chronic mitral Regurgitation 2ry to Flial MV.
- > Acute mitral Regurgitation 2ry to Flail MV.


## Flail Mitral Valve

Failure of leaflets coaptation with rapid systolic movement of the involved leaflet into the left atrium, due to rupture chordae tendineae or papillary muscle.


➤ May result in acute, subacute or chronic MR.


# ANATOMY








# Coaptation Zone
















Lang RM, Tsang W, Weinert L, Mor-Avi V, Chandra S. J Am Coll Cardiol 2011 November 1;5 8(19):1933-1944.




Carpentier

Modified Carpentier





# **Anatomy Revisited**




0°: Midesophageal 4-chamber

60°: Commisural view

90°: Midesophageal 2-chamber


120°: Midesophageal long axis







d. TG mid SAX

e. TG two chamber






# Carpentio




### Type II: Increased leaflet motion



Ruptured chordae Elongated chordae and/ or papillary muscle

### mitral valve





Reproduced from Carpentier


sc Surg 1983;86:323-337

# Flail Mitral Valve

✓ Chronic Mitral Regurgitation


✓ Acute Mitral Regurgitation

# Chronic Mitral Valve Disease




Heart Disease and Stroke Statistics 2010 Update: A Report From the American Heart Association. *Circulation*. 2010;121:e46-e215. Nkomo VT et al. *Lancet*. 2006; 368:1005-1011.

# Mitral Regurgitation Etiologies



- ☐ Degenrative Heart Disease
- Ischemia Mitral Rgurgitation
- Endocarditis
- RHD
- □ Other

# Mitral Regurgitation Etiologies



Source: Enriquez-Sarano, M et al. Lancet. 2009;373:1382-94.


Differentiating Characteristics	<b>Barlow Disease</b>	Fibroelastic Deficiency	
Pathology	Excess leaflet tissue due to accumulation of mucopolysaccharides	Loss of mechanical integrity due to impaired production of connective tissue	
Typical age at diagnosis	Younger (< 40 years old)	Older (> 60 years old)	
Duration of disease	Years to decades	Days to months	
Physical exam	Midsystolic click and late systolic murmur	Holosystolic murmur	
Leaflet involvement	Multisegmental	Unisegmental	
Chordal lesions	Chordal thickening and elongation	Chordal elongation and chordal rupture	
Complexity of valve	More complex	Less complex	

repair

### **Fibroelastic Deficiency**

### **Barlow Disease**





### **Years**

Once the patient's EF becomes <60% and/or becomes symptomatic, mortality rises sharply.

Indications for Repair/Replacement				
	ESC/EACTS	ACC/AHA		
Symptomatic and LVEF > 30%	I	I		
Asymptomatic and LVEF 30%-60%	I	I		
Asymptomatic and LVESD ≥ 40 mm		1		
Asymptomatic and LVESD ≥ 45 mm	1			
Asymptomatic with flail leaflet and LVESD ≥ 40 mm with low surgical risk and high likelihood of repair	lla			
Asymptomatic and new onset atrial fibrillation or sPAP ≥ 50 mm	II.o.	llo		

lla IIa Hg MV repair reasonable in asymptomatic patients (LVESD < 40 mm and LVEF ≥ 60%) when likelihood of successful and durable repair without residual MR is > 95% with an lla **expected mortality rate < 1%** when performed at a Heart

Valve Center of Excellence Asymptomatic with left atrial dilation (≥ 60 mL/m2) or pulmonary hypertension on exercise (sPAP ≥ 60 mm Hg) when there is a IIb low surgical risk and high likelihood of repair.

# Indications for Repair/Replacement

> Symptoms (II-IV) at rest or exercise.

> Asymptomatic:

LV dysfunction - EF < 60%.

-ESD > 40 mm.

> Prophylactic

# MitraClip Therapy

Filling a Treatment Gap






#### **Less Invasive**







**Increased MR Reduction** 








# Selection Criteria for MitraClip Insertion

- > Grade 3 or more out of 4 grades
- > Pathology in A2-P2 area
- ➤ Flail gap < 10 mm
- > Flail width < 15 mm
- $\triangleright$  Mitral valve orifice area  $> 4 \text{ cm}^2$
- ➤ Mobile leaflet length > 1 cm

### MV anatomical exclusions: Mitral valve orifice area <4.0cm<sup>2</sup>




# Acute Flail Mitral Valve


# 58 year old male patient. H/O DM, dyslipidemia and smoking. Admitted as a case of inferior STEMI.



### Day after patient developed sudden SOB, and desaturation. New apical soft murmur and bilateral lung crackles.







### Acute mitral regurgitation 2ry to flail MV


> Complication of myocardial infarction or Infective Endocarditis.

- ➤ Partial or total rupture of a papillary muscle induced sudden massive MR.
- Total rupture of a LV papillary muscle is often fatal.

➤ Partial rupture of papillary muscle is not necessarily overwhelming MR.

### Acute Flail MV due to STEMI

- Approximately 1%.
- > posteromedial > anterolateral.
- ➤ Occurs with a relatively small infarction.
- Rupture of a RV papillary muscle is unusual.



- ✓ Acute rupture/ flail induced sudden massive MR
- ✓ Large amount of blood into small and noncompliant LA.
- ✓ Rapid equalization of pressures between the LA and LV.

Abrupt increase LA and Wedge pressure

Low stroke volume


Significant V wave


Tachycardia LV hypercontractility


Pulmonary edema

Cardiogenic Shock

### Ruptured chordae tendineae and acute mitral insufficiency








# Management

- ➤ Invasive monitoring in most cases once recognition complication of STEMI.
- ➤ Vasodilator therapy, (nitroglycerin or nitroprusside), once systolic BP > 90 mm Hg.
- ➤ Inotropes may also be needed to support adequate cardiac output.
- ➤ IAB counterpulsation should be instituted rapidly (If pharmacologic therapy is not tolerated or fails to achieve)


## Sodium Nitroprusside effect



Grossman's Cardiac Catheterization

# Surgery

- ➤ In most cases, surgery should not be delayed in patients with a correctable lesion and require pharmacologic and mechanical support.
- ➤ In a subset of patients whose hemodynamic status remains stable, the operation may be postponed for 2 to 4 weeks to allow some healing of the infarct.




operative mortality (odds ratio, 0.18; 95% CI, 0.04 to 0 after surgery after 1990 (odds ratio, 0.28; 95% CI, 0.06 from 67% up to 1990 without coronary artery bypass graf 5-year survival was  $65\pm7\%$ , and survival free of conge operative survivors was  $79\pm4\%$ , identical (P=0.24) to fraction, MI location, and MI year). Survival free of cong (10-year survival,  $28\pm8\%$  versus  $36\pm6\%$ ; P=0.46).

Conclusions—Surgery for post-MI PMR involves a notal operative risk, particularly with associated coronary arte to that of similar MI without PMR. These encouraging of aggressive therapeutic approach for patients incurring P.

### ılar Surgery

# rgical Correction of Mitral apillary Muscle Rupture

sco Grigioni, MD; Véronique L. Roger, MD, MPH; tell V. Schaff, MD; Maurice Enriquez-Sarano, MD



## STEMI with a loud systolic murmur

	VENTRICULAR SEPTAL RUPTURE	PAPILLARY MUSCLE RUPTURE	Dynamic LVOT Obstruction
Territory	Anterior and Inferior	Inferior > Antterior	Mainly Anterior
Sings	Thrill, SOB, hypotension, Biventricular failure.	SOB, hypotension, pulmonary edema	Hypotension, tachycardia.
TTE, TEE	Septal rupture with left-to- right shunt on color Dp pattern of RV overload	Hypercontractile LV, chaotic motion, flail MV leaflet, severe MR on color Dp.	SAM with LVOT Obstruction
Rt Heart Cath	High PCWP with Oxygen saturation > 10% RARV	Large <i>v</i> waves, very high PCWP. With No increase in oxygen saturation from the RA to RV.	
Treatment	Surgery/Intervention	Surgery	Medical therapy

# Thank you

